Collapsible tube embodiments may be used to promote hemostasis at surgical sites or any other suitable location. In some cases, vascular closure device embodiments may include collapsible tube embodiments in order to promote hemostasis at a surgical site during a vascular closure procedure.

The present invention relates, in part, to hydrophobically-modified polymers and foams and their use in the control of bleeding.

A hemostatic material or a tissue sealant, wherein a main component of the hemostatic material or the tissue sealant or part of the hemostatic material or the tissue sealant is a sponge grown in sea water or fresh water.

An embolic device for treating aneurysms or other vascular disorders may be more compliant than conventional devices, while still achieving desired porosity. In particular, the device may achieve the desired porosity only at discrete sections along the length of the device where such a porosity is required (e.g., sections that will block the neck of the aneurysm upon deployment). The remaining sections of the device can be configured to increase the device's compliance. For example, the remaining sections can be formed from less material than the sections with the desired porosity. In some instances, the sections with the desired porosity are formed from mesh-screen segments and the remaining sections are formed from coil segments. In some instances, the mesh-screen segments are configured to further enhance the device's compliance. For example, the mesh-screen segment can be formed from a layered structure that achieves greater compliance than conventional braided structures.

The present embodiments provide systems and medical formulations suitable for delivering therapeutic powders to a target site. In one embodiment, the system comprises a delivery device, a first powder being formed of particles of a first material, and a second powder being formed of particles of a second material, wherein the second material is different than the first material. At least some of the particles of the first powder and the second powder are bound together to form bonded particles. The bonded particles are simultaneously delivered to the target site by the delivery device. In one embodiment, a medical formulation may comprise carbomer present in a range between about 60-80% by weight of the formulation, bentonite present in a range of between about 5-15% by weight of the formulation, and calcium carbonate present in a range of between about 10-30% by weight of the formulation.

A hemostatic biopsy tract article includes a bioresorbable body having a microporous structure. The bioresorbable body is formed by a mixture that includes a bioabsorbable hemostatic powder, a hydrolyzed starch, hyaluronic acid, and carboxymethylcellulose. Optionally, a marker element may be coupled to the bioresorbable body, wherein the marker element is formed from a material that is imageable under at least one imaging modality.

Compositions and methods related to flowable hemostats that crosslink during and/or after application to a bleeding site are generally described.

Compositions and methods related to powdered hemostats that crosslink during and/or after application to a bleeding site are generally described.

A stent having an inner surface and an outer surface, the stent comprising a coating composition comprising a platelet-activated adhesive on at least a portion of the outer surface thereof.

Systems and methods related to polymer foams are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to a body cavity and placed in contact with, for example, tissue, injured tissue, internal organs, etc. In some embodiments, the polymer foams can be formed within a body cavity (i.e., in situ foam formation). In addition, the foamed polymers may be capable of exerting a pressure on an internal surface of a body cavity and preventing or limiting movement of a bodily fluid (e.g., blood, etc.).